CARsgen: CARsgen Therapeutics announces positive results from China GC/GEJ pivotal phase II trial of Claudin18.2 CART
CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T─cell therapies for the treatment of hematologic malignancies and solid tumours, announces the positive results from the
Read full article »
CEO
Zonghai Li
CARsgen is a China-based biotechnology company that develops and commercializes T-cell therapeutics for the treatment of cancer.
Read more